Cell & Gene Therapies (CGT) offer potentially curative treatment to patients with chronic and hereditary conditions but carry high price tags. One proposal to overcome such financing challenges is to create a national risk pool.
House Energy and Commerce Subcommittee on Oversight and Investigations Holds Hearing on State Medicaid Program Integrity and Health Price Transparency
On June 25, the House Energy and Commerce Oversight and Investigations Subcommittee held a hearing titled “State Medicaid Program Integrity: Examining Fraud Risks and Oversight Deficiencies.” The hearing featured state Medicaid program directors from Minnesota, California, New York, and Ohio, who testified to strategies they’ve implemented to insure Medicaid program integrity in their states.
Read AMCP's summary.
Related
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to Medicare Drug Price Negotiation Program: Draft Guidance, Manufacturer Effectuation of the Maximum Fair Price in 2028 (Draft Guidance). CMS issued this draft guidance to describe the processes and requirements for manufacturer effectuation of the maximum fair price (MFP) in 2028 for selected drugs payable under Medicare Part B and/or covered under Medicare Part D.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) for the opportunity to provide comments in response to the Request for Information: Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making (RFI).
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
